In the pan‐cancer analysis, compared with normal tissue, ITGB1 is significantly overexpression in various tumors, including stomach adenocarcinoma (STAD), head and neck squamous cell carcinoma (HNSC), esophageal carcinoma (ESCA), cholangiocarcinoma (CHOL) pheochromocytoma and paraganglioma (PCPG), renal clear cell carcinoma (KIRC), and hepatocellular carcinoma (LIHC) (Figure 1A, p < 0.05). Here, ITGB1 is linked to paraganglioma.